@Rap - Initially, I thought the same thing - that they brought him on board because of his expertise in commercialization and navigating the FDA approval process. And, while I'm sure that's true, I do find one thing fairly puzzling. I was reading a bit about Athenex, and it would seem that they could be viewed as a competitor of Delcath. So it begs the question: How does Dr. Pedder not have a conflict of interest serving on the board of a company that is a potential competitor? Unless, there is something else in play ....